Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis
We demonstrate that the histone deacetylase (HDAC) inhibitor drug trichostatin A (TSA)
reduces spinal cord inflammation, demyelination, neuronal and axonal loss and ameliorates
disability in the relapsing phase of experimental autoimmune encephalomyelitis (EAE), a
model of multiple sclerosis (MS). TSA up-regulates antioxidant, anti-excitotoxicity and pro-
neuronal growth and differentiation mRNAs. TSA also inhibits caspase activation and down-
regulates gene targets of the pro-apoptotic E2F transcription factor pathway. In splenocytes …
reduces spinal cord inflammation, demyelination, neuronal and axonal loss and ameliorates
disability in the relapsing phase of experimental autoimmune encephalomyelitis (EAE), a
model of multiple sclerosis (MS). TSA up-regulates antioxidant, anti-excitotoxicity and pro-
neuronal growth and differentiation mRNAs. TSA also inhibits caspase activation and down-
regulates gene targets of the pro-apoptotic E2F transcription factor pathway. In splenocytes …